CD4 T cell response has been widely overlooked in cancer immunotherapy, but recently gained more attention as Th1 and Th17 CD4 T cells have been shown to contribute to anti-tumoral immune responses by promoting CD8 T cell recruitment and activation or by secreting inflammatory cytokines (24, 25). The gene discussed is CD8A; the disease is cancer.